Addition of gonadotropin releasing hormone antagonist for women undergoing intrauterine insemination: a randomized controlled trial

Lakshmi Gopal; Pradeepa Sudhakar; Dhanabagyam Kandaswami; Saranya Manivannan

doi:10.18203/2320-1770.ijrcog20230821

Authors

Lakshmi Gopal Department of Obstetrics and Gynecology, Sudha Hospitals, Salem, Tamil Nadu, India https://orcid.org/0000-0001-9645-7854
Pradeepa Sudhakar Department of Reproductive Medicine, Sudha Hospitals, Erode, Tamil Nadu, India https://orcid.org/0000-0002-9423-4742
Dhanabagyam Kandaswami Department of Reproductive Medicine, Sudha Hospital, Coimbatore, Tamil Nadu, India
Saranya Manivannan Department of Obstetrics and Gynecology, Sudha Hospitals, Erode, Tamil Nadu, India https://orcid.org/0000-0002-3522-777X

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20230821

Keywords:

Cetrorelix, Antagonist, Ovarian stimulation, Clinical pregnancy, Stimulation

Abstract

Background: Intrauterine insemination (IUI) is a widely acceptable fertility treatment modality. GnRH antagonists have been proven effective in restricting the LH surge. The aim of the study was to assess whether the addition of gonadotropin releasing hormone antagonist (Cetrorelix) would improve clinical pregnancy rate in women undergoing IUI.

Methods: This prospective randomized controlled trial was conducted at a Sudha fertility center where 730 women with primary or secondary infertility were subjected to controlled ovarian stimulation with tablet letrozole 5mg once daily for 5 days and then human menopausal gonadotrophins 75 IU/150 IU administered intramuscularly for both the groups and for study group alone Cetrorelix (0.25 mg/day, started when the leading follicle was ≥16 mm; GnRH antagonist) was given additionally. A double insemination was performed at 36 hours and 60 hours after hCG was given (5,000 IU, intramuscularly) in both groups. Chi-square and independent t test was done.

Results: Baseline characteristics in both the groups were almost equal without any statistically significant difference. Significant difference (p=0.017) was found on calculating with statistics among both groups on analyzing LH on hCG day. Clinical pregnancy rates (29.3%) were higher among the study group compared with the control group (21.7%).

Conclusions: From the present study results it shows that addition of GnRH antagonists to controlled ovarian stimulation IUI significantly decreases the incidence of premature luteinization and increases the clinical pregnancy rates and live birth rate.

Metrics

Metrics Loading ...

References

Monraisin O, Chansel-Debordeaux L, Chiron A, Floret S, Cens S, Bourrinet S, et al. Evaluation of intrauterine insemination practices: a 1-year prospective study in seven French assisted reproduction technology centers. Fertil Steril. 2016;105(6):1589-93.

Cantineau AEP, Cohlen BJ, Klip H, Heineman MJ, Collaborators DISG, Hoek A, et al. The addition of GnRH antagonists in intrauterine insemination cycles with mild ovarian hyperstimulation does not increase live birth rates a randomized, double-blinded, placebo-controlled trial. Hum Reprod. 2011;26(5):1104-11.

Bensdorp A, Cohlen BJ, Heineman MJ, Vanderkerchove P. Intra‐uterine insemination for male subfertility. Cochrane Database Syst Rev. 2007;(4):32-9.

Merviel P, Heraud MH, Grenier N, Lourdel E, Sanguinet P, Copin H. Predictive factors for pregnancy after intrauterine insemination (IUI): an analysis of 1038 cycles and a review of the literature. Fertil Steril. 2010;93(1):79-88.

ESHRE Capri Workshop Group. Intrauterine insemination. Hum Reprod Update. 2009;15(3):265-77.

Bakas P, Konidaris S, Liapis A, Gregoriou O, Tzanakaki D, Creatsas G. Role of gonadotropin-releasing hormone antagonist in the management of subfertile couples with intrauterine insemination and controlled ovarian stimulation. Fertil Steril. 2011; 95(6):2024-8.

Graziano A, Caserta D, Piva I, Lo Monte G, Bordi G, Martini F, Tognon M, Marci R. The addition of GnRH antagonists in intrauterine insemination cycles: a pilot study. Eur Rev Med Pharmacol Sci. 2013;17(12):1604-10.

Lambalk CB, Leader A, Olivennes F, Fluker MR, Nyboe Andersen A, Ingerslev J, et al. Treatment with the GnRH antagonist ganirelix prevents premature LH rises and luteinization in stimulated intrauterine insemination: results of a double-blind, placebo-controlled, multicentre trial. Human Reprod. 2006;21: 632-9.

Schoemaker J, Homburg R, Lambalk CB. Dose-finding study of daily GnRH antagonist for the prevention of premature LH surges in IVF/ICSI patients: optimal changes in LH and progesterone for clinical. Reproduction. 2005.

Alisch A, Roiha K, Finas D, Felberbaum R. Extreme suppression of LH within 3 hours after GnRH-antagonist administration in COH: Results of pulsatility pattern analysis. Hum Reprod. 210;21:31-8.

Olivennes F, Diedrich K, Frydman R, Felberbaum RE, Howles CM. Safety and efficacy of a 3 mg dose of the GnRH antagonist cetrorelix in preventing premature LH surges: report of two large multicentre, multinational, phase IIIb clinical experiences. Reprod Bio Med. 2003;6:432-8.

Al-Inany HG, Youssef MA, Ayeleke RO, Brown J, Lam WS, Broekmans FJ. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2016; 4(8):CD001750.

Mochtar MH, Dutch Ganirelix Study Group. The effect of an individualized GnRH antagonist protocol on folliculogenesis in IVF/ICSI. Hum Reprod. 2004; 19(8):1713-8.

Olivennes F, Cunha-Filho JS, Fanchin R, Bouchard P, Frydman R. The use of GnRH antagonists in ovarian stimulation. Hum Reprod Update. 2002;8(3):279-90.

Gómez-Palomares JL, Acevedo-Martín B, Chávez M, Manzanares MA, Ricciarelli E, Hernández ER. Multifollicular recruitment in combination with gonadotropin-releasing hormone antagonist increased pregnancy rates in intrauterine insemination cycles. Fertil Steril. 2008;89(3):620-4.

Lambalk CB, Leader A, Olivennes F. Treatment with the GnRH antagonist ganirelix prevents premature LH rises and luteinization in stimulated intrauterine insemination: results of a double-blind, placebo Human. 2006.

Allegra A, Marino A, Coffaro F, Scaglione P, Sammartano F, Rizza G, et al. GnRH antagonist-induced inhibition of the premature LH surge increases pregnancy rates in IUI-stimulated cycles. A prospective randomized trial. Hum Reprod. 2007; 22(1):101-8.

Kosmas IP, Tatsioni A, Kolibianakis EM, Verpoest W, Tournaye H, Van der Elst J, et al. Effects and clinical significance of GnRH antagonist administration for IUI timing in FSH superovulated cycles: a meta-analysis. Fertil Steril. 2008;90(2):367-72.